Drug
Liraglutide
Liraglutide: highest development phase Post-Market, developed by Novo Nordisk. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| liraglutide NCT02008682 | Post-Market | Diabetes |
| SAXENDA | Approved | |
| Liraglutide NCT02043054 | Phase 3 | Type 2 Diabetes Mellitus |
| Liraglutide NCT02092896 | Phase 3 | Diabetes |
| liraglutide NCT00318422 | Phase 3 | Diabetes |
| Liraglutide NCT02284230 | Phase 2 | Kidney Failure, Chronic |
| liraglutide NCT01206101 | Phase 2 | Diabetes |
| liraglutide NCT01515553 | Phase 1 | Diabetes |
Latest
Follow Liraglutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.